相关临床试验
1
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
尚未招募
1
100.0%
暂无批准数据
- Telomir Pharmaceuticals published preclinical data in the Journal of Oncology Research and Therapy demonstrating Telomir-Zn suppresses tumor growth in triple-negative breast cancer and prostate cancer models through selective modulation of intracellular iron and copper. - Iron-rescue experiments provided direct proof that Telomir-Zn's anti-cancer activity depends on iron depletion, with cancer cell killing reversed when iron was added back to treated TNBC cells. - Telomir-Zn demonstrated a greater than 50-fold selectivity window, killing iron-dependent TNBC cancer cells at low concentrations while sparing normal cells. - The compound reactivated silenced tumor-suppressor genes including STAT1, GSTP1, RASSF1A, CDKN2A, and MASPIN, and reduced metastatic dissemination in HCC1806 xenografts, supporting advancement toward a planned Phase 1/2 clinical trial.
- Telomir Pharmaceuticals completed its acquisition of TELI Pharmaceuticals on April 24, 2026, securing global rights to its lead candidate Telomir-1 (Telomir-Zn) under a unified corporate structure. - The transaction provides $1.0 million in immediate funding with potential for up to $4.0 million in additional milestone-based contributions tied to clinical development progress. - The company has submitted an IND application to the FDA for Telomir-Zn to treat advanced and metastatic triple-negative breast cancer, with plans for a Phase 1/2 clinical trial if cleared. - Telomir-1 is a small-molecule therapeutic targeting epigenetic and metabolic mechanisms, with preclinical activity in modulating intracellular metal homeostasis and genomic stability.
- Telomir Pharmaceuticals reports that Telomir-1 significantly reduces viability of aggressive triple-negative breast cancer cells through dose-dependent iron regulation mechanisms. - Laboratory studies demonstrate the compound shuts down cellular energy pathways and mitochondrial function, with effects reversible upon iron supplementation. - The discovery exploits metabolic vulnerabilities unique to aggressive cancer cells while potentially sparing healthy tissue that manages iron differently. - Telomir plans to expand testing to additional cancer types and conduct animal studies in preparation for IND submission.
- Telomir Pharmaceuticals' Telomir-1 fully reversed STAT1 gene silencing in aggressive prostate cancer cells, while Paclitaxel showed no effect and Rapamycin achieved only partial reduction. - The drug demonstrated unique ability to simultaneously reactivate both STAT1 and TMS1 tumor suppressor genes, potentially overcoming immune evasion and apoptosis resistance in cancer. - Telomir-1 did not elongate telomeres in cancer cells, reinforcing its safety profile and selective action in targeting appropriate cellular mechanisms. - Previous studies showed Telomir-1 reduced tumor volume by approximately 50% and eliminated chemotherapy-induced mortality when combined with Paclitaxel.
- Telomir-1 completely reversed epigenetic silencing of the STAT1 tumor suppressor gene in aggressive human prostate cancer cells during a 21-day preclinical study. - The compound outperformed established cancer drugs Paclitaxel and Rapamycin in reactivating critical cancer defense pathways through DNA methylation modulation. - Telomir Pharmaceuticals stock surged over 140% following the announcement, with the company preparing to file for its first IND application in the coming months. - The preclinical data represents a novel approach to cancer treatment by targeting epigenetic "off switches" that silence the body's natural tumor suppression mechanisms.
- Telomir Pharmaceuticals has secured $3 million in premium equity financing from its largest shareholder to advance Telomir-1, a first-in-class age-reversal molecule, toward an IND submission for rare disease indications by year-end. - The company's lead candidate, Telomir-1, targets five fundamental biological drivers of aging and has shown promising preclinical results across multiple conditions including Progeria, Wilson's disease, and Type 2 diabetes. - Telomir is also developing Telomir-Ag2, a novel stabilized Silver(II) compound with broad-spectrum antimicrobial activity against drug-resistant pathogens, addressing a global market projected to exceed $30 billion.
- Telomir Pharmaceuticals has developed Telomir-Ag2, a stabilized Silver(II) complex showing potent activity against drug-resistant pathogens including MARSA, targeting the $30B+ antimicrobial market. - The breakthrough leverages Telomir's proprietary platform to stabilize highly reactive Silver(II) in a biologically compatible form, overcoming a major limitation that has historically prevented its medical use. - Telomir-Ag2 demonstrated superior efficacy compared to Silver(I) compounds in preclinical studies, potentially addressing urgent needs in wound care and hospital-acquired infections that cause over 10,000 deaths annually in the US alone.
- Telomir Pharmaceuticals' novel compound Telomir-1 demonstrates complete reversal of copper-induced oxidative stress in human cell lines, showing potential for treating age-related diseases and neurological disorders. - The drug exhibits strong cellular protection against copper toxicity at low doses, suggesting a unique regulatory mechanism that could transform treatments for conditions like Wilson's Disease, Alzheimer's, and AMD. - Researchers are exploring Telomir-1's potential application in treating viral infections, including avian influenza, where oxidative stress plays a crucial role in disease progression.
- Telomir Pharmaceuticals' Telomir-1 demonstrated significant copper-binding affinity in preclinical studies, suggesting its potential for treating Wilson's disease. - The company plans IND-enabling safety studies in Q2 2025, targeting an IND submission by Q4 2025, with human clinical trials expected in H1 2026. - Telomir discontinued an osteoarthritis study in dogs due to ethical concerns, opting for a new study design with naturally affected elderly dogs. - The company is also expanding research into Type 2 diabetes, Progeria, cancer, and Alzheimer's, supported by recent financing secured at a 20% premium.
